Skip to main content
. 2021 Dec 14;7(3):436–443. doi: 10.1016/j.ekir.2021.12.013

Figure 1.

Figure 1

Outcomes for participants with and without MRA use at baseline. (a) Outcomes for the primary composite, the secondary kidney-specific composite outcome, eGFR decline ≥50%, ESKD, hospitalization for heart failure or CV death, and all-cause death. (b) Cumulative incidence of the secondary kidney-specific outcome. CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; MRA, mineralocorticoid receptor antagonist.